Leo International Precision Health (LIPH) is building an active healthcare platform that unites AI-driven precision health assets across biotech, medtech, healthtech and healthcare services.
As a leader in precision diagnostics and digital health solutions across Southeast Asia, Pathomics Health harnesses advanced AI and data-driven technologies to enable personalized prevention, diagnosis, and treatment. Adding Pathomics Health to LIPH’s portfolio seamlessly complements LIPH’s vision to integrate innovative technologies for comprehensive patient care.
Pathomics Health is a Singapore headquartered company specializing in precision diagnostics and digital preventive health innovation. The company operates across two core segments, focusing on precision oncology diagnostics and preventive health management. It also offers a clinically validated in-house 1p/19q marker test for oligodendroglioma diagnostics.
With its proprietary PathGene assays and the AI-driven P7 platform, Pathomics enables predictive risk profiling and end-to-end digital health management across cancer and chronic diseases.
Find out more about Pathomics Health: https://lnkd.in/dPtfhqBz
